MCID: PRT013
MIFTS: 61

Portal Hypertension

Categories: Cardiovascular diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Portal Hypertension

MalaCards integrated aliases for Portal Hypertension:

Name: Portal Hypertension 12 75 53 29 15 17 33
Hypertension, Portal 53 44 72
Hypertension Portal 55

Classifications:



External Ids:

Disease Ontology 12 DOID:10762
ICD9CM 35 572.3
MeSH 44 D006975
NCIt 50 C3119
SNOMED-CT 68 34742003
ICD10 33 K76.6
UMLS 72 C0020541

Summaries for Portal Hypertension

NIH Rare Diseases : 53 Portal hypertension is abnormally high blood pressure in branches of the portal vein, the large vein that brings blood from the intestine to the liver. Portal hypertension itself does not cause symptoms, but complications from the condition can lead to an enlarged abdomen, abdominal discomfort, confusion, drowsiness and internal bleeding. It may be caused by a variety of conditions, but cirrhosis is the most common cause in Western countries. Treatment is generally directed toward the cause of the condition, although emergency treatment is sometimes needed for serious complications.

MalaCards based summary : Portal Hypertension, also known as hypertension, portal, is related to esophageal varix and hypersplenism, and has symptoms including signs and symptoms, digestive An important gene associated with Portal Hypertension is DGUOK (Deoxyguanosine Kinase), and among its related pathways/superpathways are Signaling by GPCR and Response to elevated platelet cytosolic Ca2+. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 75 Portal hypertension is hypertension (high blood pressure) in the hepatic portal system - made up of the... more...

Related Diseases for Portal Hypertension

Diseases related to Portal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 716)
# Related Disease Score Top Affiliating Genes
1 esophageal varix 33.4 SST F2 ALB
2 hypersplenism 32.4 THPO F2 ALB
3 varicose veins 31.9 VWF VEGFA F2
4 hepatic coma 31.8 GPT F2 ALB
5 schistosomiasis 31.7 TNF F2 ALB
6 gastric antral vascular ectasia 31.6 SST CTC1
7 peritonitis 31.4 TNF F2 ALB
8 hepatic encephalopathy 31.4 TNF GPT F2 ALB
9 hepatorenal syndrome 31.3 F2 EDN1 ALB ACE
10 hepatoportal sclerosis 31.1 GPT F2 ACE
11 liver disease 31.1 TNF PKHD1 GPT F2 ALB
12 pancreas disease 30.9 TNF SST ALB
13 acute liver failure 30.8 GPT F2 ALB
14 abdominal tuberculosis 30.8 F2 ALB
15 cholangitis 30.8 TNF GPT F2 ALB
16 active peptic ulcer disease 30.8 VWF F2
17 cholelithiasis 30.7 SST GPT ALB
18 viral hepatitis 30.7 TNF GPT F2 ALB
19 bilirubin metabolic disorder 30.7 GPT F2 ALB
20 angiodysplasia 30.6 VWF VEGFA SST
21 iga glomerulonephritis 30.5 ALB AGTR1 ACE
22 choledocholithiasis 30.5 GPT F2 ALB
23 hepatic tuberculosis 30.4 GPT F2 ALB
24 alcoholic hepatitis 30.4 TNF GPT F2 ALB
25 end stage renal failure 30.4 TNF ALB AGTR1 ACE
26 cholecystitis 30.3 GPT F2 ALB
27 obstructive jaundice 30.3 TNF GPT F2 EDN1 ALB
28 hepatitis b 30.3 TNF GPT F2 ALB
29 respiratory failure 30.3 TNF ALB ACE
30 raynaud phenomenon 30.3 VWF EDN1 AGTR1
31 jejunoileitis 30.2 TNF NOS3 ALB
32 congestive heart failure 30.2 UTS2 EDN1 AGTR1 ACE
33 thrombocytosis 30.2 THPO JAK2 F2
34 wilson disease 30.1 GPT F2 ALB
35 liver cirrhosis 30.1 UTS2 THPO SST GPT F2 EDN1
36 pulmonary embolism 30.1 VWF F2 ALB
37 hepatitis a 30.1 TNF GPT F2 ALB
38 kwashiorkor 30.1 GPT F2 ALB
39 infantile liver failure syndrome 1 30.1 GPT F2 ALB
40 intestinal disease 30.1 VEGFA TNF ALB
41 ischemia 30.0 VEGFA NOS3 EDN1 ACE
42 myeloma, multiple 30.0 VEGFA TNF JAK2 ALB
43 membranous nephropathy 29.9 TNF ALB ACE
44 vein disease 29.9 VEGFA SST F2 ALB
45 splenic disease 29.6 THPO F2 ALB
46 connective tissue disease 29.5 TNF EDNRA EDN1 BMPR2 ACE
47 gastrointestinal system disease 29.4 VEGFA TNF SST F2 ALB
48 acute myocardial infarction 29.3 VWF EDN1 AGTR1 ACE
49 atrial fibrillation 29.2 VWF F2 AGTR1 ACE
50 hellp syndrome 29.2 VWF GPT F2 EDN1

Comorbidity relations with Portal Hypertension via Phenotypic Disease Network (PDN): (show all 21)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Deficiency Anemia
Esophageal Varix Heart Disease
Hepatic Encephalopathy Hepatitis
Hepatocellular Carcinoma Hepatorenal Syndrome
Hypersplenism Iron Deficiency Anemia
Neutropenia Portal Vein Thrombosis
Primary Biliary Cirrhosis Protein-Energy Malnutrition
Urea Cycle Disorder

Graphical network of the top 20 diseases related to Portal Hypertension:



Diseases related to Portal Hypertension

Symptoms & Phenotypes for Portal Hypertension

UMLS symptoms related to Portal Hypertension:


signs and symptoms, digestive

MGI Mouse Phenotypes related to Portal Hypertension:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 ACE AGTR1 ALB BMPR2 CTC1 EDN1
2 growth/size/body region MP:0005378 10.32 ACE AGTR1 BMPR2 CTC1 EDN1 EDNRA
3 hematopoietic system MP:0005397 10.31 ACE AGTR1 BMPR2 CTC1 EDNRA F2
4 immune system MP:0005387 10.3 ACE AGTR1 BMPR2 CTC1 EDNRA F2
5 cardiovascular system MP:0005385 10.29 ACE AGTR1 BMPR2 EDN1 EDNRA F2
6 mortality/aging MP:0010768 10.28 ACE AGTR1 ALB BMPR2 CTC1 EDN1
7 digestive/alimentary MP:0005381 10.24 ALB EDN1 EDNRA F2 NOS3 PKHD1
8 endocrine/exocrine gland MP:0005379 10.22 ACE ALB CTC1 EDN1 EDNRA JAK2
9 nervous system MP:0003631 10.06 AGTR1 BMPR2 EDN1 EDNRA F2 NOS3
10 liver/biliary system MP:0005370 10.03 ACE ALB JAK2 NOS3 PKHD1 TNF
11 normal MP:0002873 9.96 ALB BMPR2 EDN1 EDNRA F2 JAK2
12 muscle MP:0005369 9.91 ALB BMPR2 EDN1 EDNRA NOS3 TNF
13 renal/urinary system MP:0005367 9.81 ACE AGTR1 ALB BMPR2 EDN1 EDNRA
14 respiratory system MP:0005388 9.5 BMPR2 EDNRA F2 NOS3 PKHD1 TNF
15 skeleton MP:0005390 9.32 BMPR2 EDN1 EDNRA F2 GPT JAK2

Drugs & Therapeutics for Portal Hypertension

Drugs for Portal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 332)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
2
Racepinephrine Approved Phase 4 329-65-7 838
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
5
Losartan Approved Phase 4 114798-26-4 3961
6
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
7
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
8
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
9
Nitric Oxide Approved Phase 4 10102-43-9 145068
10
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
11
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
12
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
13
Thrombin Approved, Investigational Phase 4
14
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
15
Nadolol Approved Phase 4 42200-33-9 39147
16
Prazosin Approved Phase 4 19216-56-9 4893
17
Warfarin Approved Phase 4 81-81-2 6691 54678486
18
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
19
Dalteparin Approved Phase 4 9005-49-6
20
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
21
Dipyridamole Approved Phase 4 58-32-2 3108
22
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
23
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
24
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
25
Phylloquinone Approved, Investigational Phase 4 84-80-0
26
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
27 Bemiparin Approved, Investigational Phase 4 91449-79-5
28
Pantoprazole Approved Phase 4 102625-70-7 4679
29
Tranexamic Acid Approved Phase 4 1197-18-8 5526
30
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
31
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
32
Propranolol Approved, Investigational Phase 4 525-66-6 4946
33
Lactulose Approved Phase 4 4618-18-2 11333
34
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
35
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
36
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
37
Taurine Approved, Nutraceutical Phase 4 107-35-7 1123
38
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
39
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
40
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
41
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
42 Beraprost Investigational Phase 4 88430-50-6
43 Menaquinone Investigational Phase 4 1182-68-9
44 Peripheral Nervous System Agents Phase 4
45 Respiratory System Agents Phase 4
46 Anti-Asthmatic Agents Phase 4
47 Autonomic Agents Phase 4
48 Sympathomimetics Phase 4
49 Adrenergic Agonists Phase 4
50 Adrenergic alpha-Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 393)
# Name Status NCT ID Phase Drugs
1 Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial Unknown status NCT01282398 Phase 4 Simvastatin;placebo
2 Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems Unknown status NCT00332904 Phase 4 propranolol;spironolactone
3 Randomized and Controlled Study of Endoscopic Ligation, Nadolol and Isosorbide Mononitrate vs Endoscopic Ligation and Nadolol Alone, or Associated With Isosorbide Mononitrate or Prazosin, Depending of the Hemodinamyc Response Unknown status NCT00563602 Phase 4
4 RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
5 Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
6 Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding. Unknown status NCT00414713 Phase 4
7 Endoscopic Treatment Versus Propranolol for Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
8 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
9 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
10 Banding Ligation Plus Propranolol Versus Banding Ligation to Prevent Rebleeding of Esophageal Varices Unknown status NCT02740166 Phase 4 propranolol
11 Propofol and Fentanyl Versus Midazolam and Fentanyl for Sedation During Diagnostic or Therapeutic Gastrointestinal Endoscopy in Cirrhotic Patients Unknown status NCT00906139 Phase 4 Propofol;Midazolam;Fentanyl
12 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial Unknown status NCT01298284 Phase 4 propranolol
13 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
14 A Randomized Trial of GVS Alone vs. Nadolol Unknown status NCT01298271 Phase 4 propranolol
15 A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol Unknown status NCT00567216 Phase 4 Nadolol
16 The Impact of Early Feeding Following Ligation of the Acute Bleeding Varices Unknown status NCT01287702 Phase 4
17 Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
18 Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis – a Prospective Randomized Long-Term Study Unknown status NCT00239096 Phase 4 losartan (drug)
19 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
20 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
21 The Effect of Oral Taurine on Portal Hemodynamics in Patients With Advanced Completed NCT02344719 Phase 4 Taurin 6g per day per oral for 28 days;Placebo 6g per day per oral for 28 days
22 Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin Completed NCT02994485 Phase 4 Simvastatin
23 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
24 Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis Completed NCT00570622 Phase 4 Pioglitazone;Placebo
25 Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices Completed NCT00534677 Phase 4 Terlipressin;Octreotide
26 Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response. Completed NCT00450164 Phase 4 Nadolol;Isosorbide mononitrate;Prazosin
27 Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed Completed NCT00369694 Phase 4 Terlipressin;Terlipressin & then Dummy
28 Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Pulmonary Arterial Hypertension Children Associated With Left to Right Shunt Congenital Heart Defect Completed NCT03431649 Phase 4 Beraprost Sodium;Sildenafil Citrate
29 PROPRANOLOL ASSOCIATED WITH ENDOSCOPIC BAND LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES FOR PRIMARY PROPHYLAXIS OF VARICEAL BLEEDING?: A RANDOMIZED CONTROLLED TRIAL Completed NCT01893541 Phase 4 PROPRANOLOL
30 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy and Azygoportal Disconnection for Portal Hypertension Completed NCT02247414 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
31 A Controlled Trial of Nadolol Plus Isosorbide Mononitrate vs. Carvedilol for the Prevention of Variceal Rebleeding Completed NCT01103154 Phase 4 carvedilol;nadolol + ISMN
32 Comparison of Endoscopic Injection of Conventional and Double Doses Cyanoacrylate for Gastric Variceal Hemorrhage Completed NCT00735358 Phase 4
33 Prospective Detection of Liver Fibrosis With MRI Compared to Fibroscan and Blood Tests Completed NCT01600105 Phase 4 Perfusion MRI
34 Carvedilol Plus Endoscopic Cyanoacrylate Injection Versus Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding Completed NCT02504723 Phase 4 carvedilol;cyanoacrylate
35 Study of the Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis Completed NCT01686698 Phase 4
36 Short-course Somatostatin Versus Terlipressin Infusion in Combination With Endoscopic Variceal Ligation for the Prevention of Early Esophageal Variceal Rebleeding Completed NCT02757703 Phase 4 Somatostatin;Terlipressin;Pantoprazole
37 The Use of Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis: a Multicenter, Open-label Randomized Clinical Trial Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
38 A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet
39 Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study Completed NCT01769040 Phase 4 Rifaximin;placebo
40 Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
41 Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding. Completed NCT01727453 Phase 4 warfarin;Bemiparina
42 Effects of Spironolactone on Fibrosis Progression and Portal Hypertension in Patients With Compensated Cirrhosis Recruiting NCT02907749 Phase 4 Spironolactone Pill;Carvedilol;Spironolactone and Carvedilol
43 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension Recruiting NCT02489045 Phase 4 SHAPE measurement (Sonazoid ultrasoud contrast agent)
44 A Multicentre Randomized Controlled Study on the Effect of PPIs on Esophagogastric Variceal Bleeding in Cirrhotic Patients (PPIs: Proton Pump Inhibitors) Recruiting NCT03175731 Phase 4 Proton Pump Inhibitors;Placebo
45 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
46 A Prospective, Randomized Controlled Trial of 2- Day vs. 5- Day Terlipressin and Ceftriaxone in the Prevention of Very Early Rebleeding in Patients With Acute Gastroesophageal Variceal Hemorrhage Recruiting NCT04056806 Phase 4 Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial
47 Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903): A Multicenter, Single-blind, Randomised Controlled Trial Recruiting NCT04028323 Phase 4 Terlipressin;Octreotide
48 Early Precise Diagnosis and Intervention of Cirrhotic Portal Hypertension (CPT) Based on a Noninvasive 3D-virtual-model of Hepatic Portal System (3D-vHPS) Enrolling by invitation NCT02925975 Phase 4 Carvedilol
49 A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus Not yet recruiting NCT02945956 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu
50 A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Traditional Chinese Medicine Combined With Entecavir and Carvedilol in Moderate and Severe Cirrhotic Portal Hypertension Due to Hepatitis B Virus Not yet recruiting NCT02945982 Phase 4 Entecavir+Carvedilol+ Placebo;Entecavir+Carvedilol+ Fuzheng Huayu;Entecavir+Carvedilol+ Fuzheng Huayu +TCM analysis

Search NIH Clinical Center for Portal Hypertension

Cochrane evidence based reviews: hypertension, portal

Genetic Tests for Portal Hypertension

Genetic tests related to Portal Hypertension:

# Genetic test Affiliating Genes
1 Portal Hypertension 29

Anatomical Context for Portal Hypertension

MalaCards organs/tissues related to Portal Hypertension:

41
Liver, Spleen, Kidney, Endothelial, Testes, Colon, Pancreas

Publications for Portal Hypertension

Articles related to Portal Hypertension:

(show top 50) (show all 17527)
# Title Authors PMID Year
1
Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. 9 38
20428787 2010
2
Long-acting somatostatin analogue therapy in obscure-overt gastrointestinal bleeding in noncirrhotic portal hypertension: a case report and literature review. 9 38
19491695 2010
3
Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. 9 38
19582578 2010
4
Long-term outcome and management of hepatopulmonary syndrome in children. 9 38
19686444 2010
5
Portal hypertension in primary biliary cirrhosis (PBC): A reversible condition? Yes, but not in all UDCA treated patients. 9 38
19796042 2009
6
Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats. 9 38
19797237 2009
7
Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. 9 38
19446911 2009
8
Reticulated platelets and thrombopoietin in schistosomiasis patients. 9 38
19143871 2009
9
Ascites: aetiology, mortality and the prevalence of spontaneous bacterial peritonitis. 9 38
19440927 2009
10
Pathobiology of secondary immune thrombocytopenia. 9 38
19245930 2009
11
Innate immune dysfunction in acute and chronic liver disease. 9 38
20047110 2009
12
Anicteric cholangiopathy in schistosomiasis patients. 9 38
18598665 2008
13
Cannabinoid receptors as therapeutic targets in the management of liver diseases. 9 38
19259549 2008
14
Increased circulating urotensin II in cirrhosis: potential implications in liver disease. 9 38
17913301 2008
15
Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. 9 38
18318439 2008
16
[The role of urotensin II in human pathophysiology]. 9 38
19323069 2008
17
[Analysis of risk factors for selective devascularization in patients with portal hypertension]. 9 38
18509995 2008
18
High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. 9 38
17918268 2007
19
New angiotensin II type 1 receptor blocker olmesartan improves portal hypertension in patients with cirrhosis. 9 38
17608670 2007
20
Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. 9 38
18023093 2007
21
Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. 9 38
17919235 2007
22
Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. 9 38
17958515 2007
23
Right liver lobe/albumin ratio: contribution to non-invasive assessment of portal hypertension. 9 38
17879402 2007
24
Other immune thrombocytopenias. 9 38
18096469 2007
25
The puzzle of endothelial nitric oxide synthase dysfunction in portal hypertension: The missing piece? 9 38
17879360 2007
26
Significance of enhanced expression of nitric oxide syntheses in splenic sinus lining cells in altered portal hemodynamics of idiopathic portal hypertension. 9 38
17417733 2007
27
Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension. 9 38
17608860 2007
28
The role of thrombopoietin and spleen volume in thrombocytopenia of patients with noncirrhotic and cirrhotic portal hypertension. 9 38
17602356 2007
29
Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. 9 38
17337499 2007
30
Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. 9 38
17174610 2007
31
A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. 9 38
17416468 2007
32
Q-T interval (QT(C)) in patients with cirrhosis: relation to vasoactive peptides and heart rate. 9 38
17852825 2007
33
[Prevention and treatment of esophageal variceal bleeding]. 9 38
17378164 2006
34
New insights into the coagulopathy of liver disease and liver transplantation. 9 38
17203512 2006
35
Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. 9 38
16434427 2006
36
Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. 9 38
16919014 2006
37
Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. 9 38
16771945 2006
38
Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. 9 38
16573786 2006
39
GRK2 makes trouble: a no-NO in portal hypertension. 9 38
16530538 2006
40
Myosin phosphatase isoform switching in vascular smooth muscle development. 9 38
16356512 2006
41
[Hepatorenal syndrome]. 9 38
17203812 2006
42
Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis. 9 38
15955217 2005
43
Expression of angiotensin II type 1 receptor in human cirrhotic livers: Its relation to fibrosis and portal hypertension. 9 38
15905119 2005
44
The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. 9 38
15929762 2005
45
[A study of the association of iNOS and eNOS gene polymorphism with portal hypertension in liver cirrhosis]. 9 38
15918973 2005
46
Effect of somatostatin versus octreotide on portal haemodynamics in patients with cirrhosis and portal hypertension. 9 38
15647641 2005
47
Urotensin II: its function in health and its role in disease. 9 38
15883758 2005
48
Hepatorenal syndrome. 9 38
15920325 2005
49
[Factors influencing clinical course of viral hepatitis]. 9 38
16381233 2005
50
Hepatorenal syndrome. 9 38
15381144 2005

Variations for Portal Hypertension

Expression for Portal Hypertension

Search GEO for disease gene expression data for Portal Hypertension.

Pathways for Portal Hypertension

Pathways related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 VWF VEGFA UTS2 TNF SST NOS3
2
Show member pathways
13.1 VWF VEGFA THPO NOS3 JAK2 F2
3
Show member pathways
12.82 UTS2 THPO JAK2 F2 AGTR1 ACE
4
Show member pathways
12.67 TNF NOS3 JAK2 F2 EDN1 AGTR1
5
Show member pathways
12.25 TNF NOS3 JAK2 F2 AGTR1
6 11.75 VEGFA NOS3 EDN1
7
Show member pathways
11.69 VWF THPO F2
8 11.51 EDNRA AGTR1 ACE
9 11.5 VEGFA TNF NOS3 EDN1 BMPR2
10 11.31 VEGFA NOS3 EDN1
11 11.27 JAK2 EDNRA EDN1
12 11.1 VEGFA TNF NOS3 JAK2 EDN1 AGTR1
13 10.96 NOS3 EDNRA EDN1
14
Show member pathways
10.81 VEGFA JAK2 EDN1

GO Terms for Portal Hypertension

Cellular components related to Portal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 VWF VEGFA UTS2 TNF THPO SST
2 caveola GO:0005901 9.5 NOS3 JAK2 BMPR2
3 platelet alpha granule lumen GO:0031093 9.43 VWF VEGFA ALB
4 extracellular space GO:0005615 9.36 VEGFA UTS2 TNF THPO SST GPT
5 Weibel-Palade body GO:0033093 9.16 VWF EDN1

Biological processes related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.93 VEGFA TNF EDN1 ACE
2 in utero embryonic development GO:0001701 9.88 VEGFA NOS3 EDNRA EDN1
3 positive regulation of cell proliferation GO:0008284 9.88 VEGFA THPO PKHD1 JAK2 F2 EDN1
4 positive regulation of protein phosphorylation GO:0001934 9.83 VEGFA TNF THPO F2
5 positive regulation of inflammatory response GO:0050729 9.8 TNF JAK2 AGTR1
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.79 TNF JAK2 F2
7 regulation of inflammatory response GO:0050727 9.78 TNF JAK2 AGTR1
8 positive regulation of cytosolic calcium ion concentration GO:0007204 9.78 JAK2 EDNRA EDN1 AGTR1
9 positive regulation of MAP kinase activity GO:0043406 9.77 VEGFA TNF EDN1
10 positive regulation of endothelial cell migration GO:0010595 9.69 VEGFA EDN1 BMPR2
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 TNF JAK2 EDN1
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.63 TNF JAK2 EDN1
13 artery smooth muscle contraction GO:0014824 9.62 EDNRA EDN1
14 negative regulation of platelet activation GO:0010544 9.62 NOS3 F2
15 kidney development GO:0001822 9.62 VEGFA PKHD1 AGTR1 ACE
16 endothelial cell apoptotic process GO:0072577 9.6 TNF BMPR2
17 regulation of glucose transmembrane transport GO:0010827 9.58 EDNRA EDN1
18 positive regulation of axon extension involved in axon guidance GO:0048842 9.57 VEGFA BMPR2
19 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.55 AGTR1 ACE
20 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.54 NOS3 EDN1
21 blood vessel remodeling GO:0001974 9.54 NOS3 BMPR2 ACE
22 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.43 VEGFA ACE
23 branching involved in blood vessel morphogenesis GO:0001569 9.43 VEGFA EDNRA EDN1
24 regulation of vasoconstriction GO:0019229 9.33 EDN1 AGTR1 ACE
25 regulation of blood vessel diameter GO:0097746 9.13 UTS2 AGTR1 ACE
26 regulation of blood pressure GO:0008217 9.02 UTS2 NOS3 EDNRA EDN1 ACE
27 G protein-coupled receptor signaling pathway GO:0007186 10.1 UTS2 SST JAK2 F2 EDNRA EDN1

Molecular functions related to Portal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 VEGFA TNF THPO EDN1
2 signaling receptor binding GO:0005102 9.55 UTS2 THPO JAK2 F2 EDN1
3 hormone activity GO:0005179 9.26 UTS2 THPO SST EDN1
4 bradykinin receptor binding GO:0031711 8.62 AGTR1 ACE

Sources for Portal Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....